Cargando…

Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis

BACKGROUND: Nephropathic cystinosis is an inherited autosomal recessive lysosomal storage disorder characterized by the pathological accumulation and crystallization of cystine inside different cell types. WBC cystine determination forms the basis for the diagnosis and therapeutic monitoring with th...

Descripción completa

Detalles Bibliográficos
Autores principales: Elmonem, Mohamed A, Makar, Samuel H, van den Heuvel, Lambertus, Abdelaziz, Hanan, Abdelrahman, Safaa M, Bossuyt, Xavier, Janssen, Mirian C, Cornelissen, Elisabeth AM, Lefeber, Dirk J, Joosten, Leo AB, Nabhan, Marwa M, Arcolino, Fanny O, Hassan, Fayza A, Gaide Chevronnay, Héloïse P, Soliman, Neveen A, Levtchenko, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269071/
https://www.ncbi.nlm.nih.gov/pubmed/25407738
http://dx.doi.org/10.1186/s13023-014-0155-z
_version_ 1782349315903062016
author Elmonem, Mohamed A
Makar, Samuel H
van den Heuvel, Lambertus
Abdelaziz, Hanan
Abdelrahman, Safaa M
Bossuyt, Xavier
Janssen, Mirian C
Cornelissen, Elisabeth AM
Lefeber, Dirk J
Joosten, Leo AB
Nabhan, Marwa M
Arcolino, Fanny O
Hassan, Fayza A
Gaide Chevronnay, Héloïse P
Soliman, Neveen A
Levtchenko, Elena
author_facet Elmonem, Mohamed A
Makar, Samuel H
van den Heuvel, Lambertus
Abdelaziz, Hanan
Abdelrahman, Safaa M
Bossuyt, Xavier
Janssen, Mirian C
Cornelissen, Elisabeth AM
Lefeber, Dirk J
Joosten, Leo AB
Nabhan, Marwa M
Arcolino, Fanny O
Hassan, Fayza A
Gaide Chevronnay, Héloïse P
Soliman, Neveen A
Levtchenko, Elena
author_sort Elmonem, Mohamed A
collection PubMed
description BACKGROUND: Nephropathic cystinosis is an inherited autosomal recessive lysosomal storage disorder characterized by the pathological accumulation and crystallization of cystine inside different cell types. WBC cystine determination forms the basis for the diagnosis and therapeutic monitoring with the cystine depleting drug (cysteamine). The chitotriosidase enzyme is a human chitinase, produced by activated macrophages. Its elevation is documented in several lysosomal storage disorders. Although, about 6% of Caucasians have enzyme deficiency due to homozygosity of 24-bp duplication mutation in the chitotriosidase gene, it is currently established as a screening marker and therapeutic monitor for Gaucher’s disease. METHODS: Plasma chitotriosidase activity was measured in 45 cystinotic patients, and compared with 87 healthy controls and 54 renal disease patients with different degrees of renal failure (CKD1-5). Chitotriosidase levels were also correlated with WBC cystine in 32 treated patients. Furthermore, we incubated control human macrophages in-vitro with different concentrations of cystine crystals and monitored the response of tumor necrosis factor-alpha (TNF-α) and chitotriosidase activity. We also compared plasma chitotriosidase activity in cystinotic knocked-out (n = 10) versus wild-type mice (n = 10). RESULTS: Plasma chitotriosidase activity in cystinotic patients (0–3880, median 163 nmol/ml/h) was significantly elevated compared to healthy controls (0–90, median 18 nmol/ml/h) and to CKD patients (0–321, median 52 nmol/ml/h), P < 0.001 for both groups. Controls with decreased renal function had mild to moderate chitotriosidase elevations; however, their levels were significantly lower than in cystinotic patients with comparable degree of renal insufficiency. Chitotriosidase activity positively correlated with WBC cystine content for patients on cysteamine therapy (r = 0.8), P < 0.001. In culture, human control macrophages engulfed cystine crystals and released TNF-α into culture supernatant in a crystal concentration dependent manner. Chitotriosidase activity was also significantly increased in macrophage supernatant and cell-lysate. Furthermore, chitotriosidase activity was significantly higher in cystinotic knocked-out than in the wild-type mice, P = 0.003. CONCLUSIONS: This study indicates that cystine crystals are potent activators of human macrophages and that chitotriosidase activity is a useful marker for this activation and a promising clinical biomarker and therapeutic monitor for nephropathic cystinosis.
format Online
Article
Text
id pubmed-4269071
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42690712014-12-18 Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis Elmonem, Mohamed A Makar, Samuel H van den Heuvel, Lambertus Abdelaziz, Hanan Abdelrahman, Safaa M Bossuyt, Xavier Janssen, Mirian C Cornelissen, Elisabeth AM Lefeber, Dirk J Joosten, Leo AB Nabhan, Marwa M Arcolino, Fanny O Hassan, Fayza A Gaide Chevronnay, Héloïse P Soliman, Neveen A Levtchenko, Elena Orphanet J Rare Dis Research BACKGROUND: Nephropathic cystinosis is an inherited autosomal recessive lysosomal storage disorder characterized by the pathological accumulation and crystallization of cystine inside different cell types. WBC cystine determination forms the basis for the diagnosis and therapeutic monitoring with the cystine depleting drug (cysteamine). The chitotriosidase enzyme is a human chitinase, produced by activated macrophages. Its elevation is documented in several lysosomal storage disorders. Although, about 6% of Caucasians have enzyme deficiency due to homozygosity of 24-bp duplication mutation in the chitotriosidase gene, it is currently established as a screening marker and therapeutic monitor for Gaucher’s disease. METHODS: Plasma chitotriosidase activity was measured in 45 cystinotic patients, and compared with 87 healthy controls and 54 renal disease patients with different degrees of renal failure (CKD1-5). Chitotriosidase levels were also correlated with WBC cystine in 32 treated patients. Furthermore, we incubated control human macrophages in-vitro with different concentrations of cystine crystals and monitored the response of tumor necrosis factor-alpha (TNF-α) and chitotriosidase activity. We also compared plasma chitotriosidase activity in cystinotic knocked-out (n = 10) versus wild-type mice (n = 10). RESULTS: Plasma chitotriosidase activity in cystinotic patients (0–3880, median 163 nmol/ml/h) was significantly elevated compared to healthy controls (0–90, median 18 nmol/ml/h) and to CKD patients (0–321, median 52 nmol/ml/h), P < 0.001 for both groups. Controls with decreased renal function had mild to moderate chitotriosidase elevations; however, their levels were significantly lower than in cystinotic patients with comparable degree of renal insufficiency. Chitotriosidase activity positively correlated with WBC cystine content for patients on cysteamine therapy (r = 0.8), P < 0.001. In culture, human control macrophages engulfed cystine crystals and released TNF-α into culture supernatant in a crystal concentration dependent manner. Chitotriosidase activity was also significantly increased in macrophage supernatant and cell-lysate. Furthermore, chitotriosidase activity was significantly higher in cystinotic knocked-out than in the wild-type mice, P = 0.003. CONCLUSIONS: This study indicates that cystine crystals are potent activators of human macrophages and that chitotriosidase activity is a useful marker for this activation and a promising clinical biomarker and therapeutic monitor for nephropathic cystinosis. BioMed Central 2014-11-19 /pmc/articles/PMC4269071/ /pubmed/25407738 http://dx.doi.org/10.1186/s13023-014-0155-z Text en © Elmonem et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Elmonem, Mohamed A
Makar, Samuel H
van den Heuvel, Lambertus
Abdelaziz, Hanan
Abdelrahman, Safaa M
Bossuyt, Xavier
Janssen, Mirian C
Cornelissen, Elisabeth AM
Lefeber, Dirk J
Joosten, Leo AB
Nabhan, Marwa M
Arcolino, Fanny O
Hassan, Fayza A
Gaide Chevronnay, Héloïse P
Soliman, Neveen A
Levtchenko, Elena
Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis
title Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis
title_full Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis
title_fullStr Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis
title_full_unstemmed Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis
title_short Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis
title_sort clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269071/
https://www.ncbi.nlm.nih.gov/pubmed/25407738
http://dx.doi.org/10.1186/s13023-014-0155-z
work_keys_str_mv AT elmonemmohameda clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis
AT makarsamuelh clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis
AT vandenheuvellambertus clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis
AT abdelazizhanan clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis
AT abdelrahmansafaam clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis
AT bossuytxavier clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis
AT janssenmirianc clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis
AT cornelissenelisabetham clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis
AT lefeberdirkj clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis
AT joostenleoab clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis
AT nabhanmarwam clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis
AT arcolinofannyo clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis
AT hassanfayzaa clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis
AT gaidechevronnayheloisep clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis
AT solimanneveena clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis
AT levtchenkoelena clinicalutilityofchitotriosidaseenzymeactivityinnephropathiccystinosis